[HTML][HTML] Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease—a meta …
RI Mincu, LF Lampe, AA Mahabadi, R Kimmig… - Journal of Clinical …, 2021 - mdpi.com
Background: Anthracycline-based chemotherapy (ANT) remains among the most effective
therapies for breast cancer. Cardiotoxicity from ANT represents a severe adverse event and …
therapies for breast cancer. Cardiotoxicity from ANT represents a severe adverse event and …
Cardiac dysfunction of antineoplastic agents in breast cancer patients.
AM Popară-Voica, A Călin… - Romanian Journal …, 2014 - search.ebscohost.com
Cancer Therapeutics–Related Cardiac Dysfunction (CTRCD) has become one of the main
causes of morbidity and mortality in cancer survivors. If CTRCD is detected early, prompt …
causes of morbidity and mortality in cancer survivors. If CTRCD is detected early, prompt …
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab
H Sawaya, IA Sebag, JC Plana, JL Januzzi… - Circulation …, 2012 - Am Heart Assoc
Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …
associated with the use of cancer treatments escalates. The present study investigates …
Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy
MU Yood, KE Wells, SH Alford, H Dakki… - … and drug safety, 2012 - Wiley Online Library
Purpose To quantify incidence of cardiovascular outcomes in patients with advanced breast
cancer receiving cardiotoxic and non‐cardiotoxic chemotherapy. Methods This study …
cancer receiving cardiotoxic and non‐cardiotoxic chemotherapy. Methods This study …
Cardiovascular risk profile of breast cancer patients treated with anthracycline-taxane containing adjuvant chemotherapy and/or trastuzumab
666 Background: With improving longevity, post-treatment cardiovascular disorders will
become an increasingly important indicator of competing mortality in early-stage breast …
become an increasingly important indicator of competing mortality in early-stage breast …
[HTML][HTML] Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline …
RV Toma, Z Anca, OG Trifănescu… - … Medical Journal of …, 2023 - ncbi.nlm.nih.gov
Background Cardiotoxicity from radiotherapy and anti-cancer therapies have been reported
in patients with breast cancer. This study aimed to investigate the early echocardiography …
in patients with breast cancer. This study aimed to investigate the early echocardiography …
[HTML][HTML] Cardiovascular toxicities from systemic breast cancer therapy
S Guo, S Wong - Frontiers in oncology, 2014 - frontiersin.org
Cardiovascular toxicity is unfortunately a potential short-or long-term sequela of breast
cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and …
cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and …
[HTML][HTML] A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with …
E Díaz-Balboa, V González-Salvado… - BMC cardiovascular …, 2021 - Springer
Background Anthracyclines and monoclonal antibodies against human epidermal growth
factor receptor-2 (HER2) are frequently used to treat breast cancer but they are associated …
factor receptor-2 (HER2) are frequently used to treat breast cancer but they are associated …
[HTML][HTML] Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left …
PW Stoodley, DAB Richards, A Boyd, R Hui… - European journal of …, 2013 - Elsevier
Aim Anthracycline agents are undermined by their cardiotoxicity. As life expectancy
following treatment is greatly improved, techniques that ensure early detection and timely …
following treatment is greatly improved, techniques that ensure early detection and timely …
Risk of cardiomyopathy in breast cancer: how can we attenuate the risk of heart failure from anthracyclines and anti-HER2 therapies?
G Kimmick, S Dent, I Klem - Current Treatment Options in Cardiovascular …, 2019 - Springer
Purpose of review To review cardiotoxicity of and strategies to prevent cardiotoxicity from
anthracyclines and anti-HER2 agents used to treat breast cancer. Recent findings Although …
anthracyclines and anti-HER2 agents used to treat breast cancer. Recent findings Although …